BeiGene renews consulting agreement with co-founder Dr. Xiaodong Wang through Dec 2026

BeOne Medicines Ltd.

Dr. Wang will continue as Chairman of Scientific Advisory Board under same terms as prior agreement.
Annual fixed consulting fee remains $100,000; additional compensation possible at Company's discretion.
Agreement effective Jan 1, 2024 to Dec 31, 2026; cancellable by Company with 30 days' notice.
Prior consulting agreement expired Dec 31, 2023; renewal ensures continuity of scientific advisory.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.